Spero Therapeutics (SPRO) Leases (2019 - 2026)

Spero Therapeutics (SPRO) has 8 years of Leases data on file, last reported at $1.3 million in Q1 2026.

• For the quarter ending Q1 2026, Leases fell 55.81% year-over-year to $1.3 million; the trailing twelve-month figure through Mar 2026 stood at $1.3 million (down 55.81% YoY), and the FY2025 full-year result was $1.5 million, down 52.47% from the prior year.
• Leases for Q1 2026 stood at $1.3 million, down from $1.5 million in the prior quarter.
• Across five years, Leases topped out at $6.3 million in Q1 2022 and bottomed at $1.3 million in Q1 2026.
• The 5-year median for Leases is $3.9 million (2024), against an average of $3.8 million.
• The widest annual swing landed in 2022, when Leases decreased 8.76%; it then tumbled 55.81% in 2026.
• A 5-year view of Leases shows it stood at $5.1 million in 2022, then retreated by 18.91% to $4.2 million in 2023, then fell by 25.05% to $3.1 million in 2024, then plunged by 52.47% to $1.5 million in 2025, then dropped by 15.14% to $1.3 million in 2026.
• The last three Leases figures came in at $1.3 million (Q1 2026), $1.5 million (Q4 2025), and $1.5 million (Q3 2025), per Business Quant data.

Peer Comparison